Identification of the Target for a Transition Metal-α-Amino Acid Complex Antibiotic Against

Overview

Journal Front Pharmacol

Date 2021 Jul 12

PMID 34248636

Authors

George W Karpin

Joseph S Merola

Joseph O Falkinham 3rd

Affiliations

Soon will be listed here.

Abstract

Spontaneous mutants of strain mc155 resistant to (iridium-L-phenylglycine complex), an antimycobacterial antibiotic, were isolated. Based on the discovery that some -resistant mutants ( ) were also resistant to high concentrations of clarithromycin (≥250 μg/ml), but no other anti-mycobacterial antibiotics, the 23S rRNA region spanning the peptidyl transferase domain was sequenced and mutations shown to be localized in the peptidyl transferase domain of the 23S rRNA gene. Measurements showed that bound to ribosomes isolated from the -sensitive parental strain, but the ribosome binding values for the mutant reduced.

References

Falkinham 3rd J, Macri R, Maisuria B, Actis M, Sugandhi E, Williams A . Antibacterial activities of dendritic amphiphiles against nontuberculous mycobacteria. Tuberculosis (Edinb). 2012; 92(2):173-81. DOI: 10.1016/j.tube.2011.12.002. View

Jamal M, Maeda S, Nakata N, Kai M, Fukuchi K, Kashiwabara Y . Molecular basis of clarithromycin-resistance in Mycobacterium avium intracellulare complex. Tuber Lung Dis. 2000; 80(1):1-4. DOI: 10.1054/tuld.1999.0227. View

Billinger M, Olivier K, Viboud C, Montes de Oca R, Steiner C, Holland S . Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005. Emerg Infect Dis. 2009; 15(10):1562-9. PMC: 2866394. DOI: 10.3201/eid1510.090196. View

Winthrop K, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M . Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010; 182(7):977-82. DOI: 10.1164/rccm.201003-0503OC. View

Marras T, Chedore P, Ying A, Jamieson F . Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax. 2007; 62(8):661-6. PMC: 2117272. DOI: 10.1136/thx.2006.070797. View

Wallace Jr R, Zhang Y, Brown-Elliott B, Yakrus M, Wilson R, Mann L . Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis. 2002; 186(2):266-73. DOI: 10.1086/341207. View

Meier A, Kirschner P, Springer B, Steingrube V, Brown B, Wallace Jr R . Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother. 1994; 38(2):381-4. PMC: 284463. DOI: 10.1128/AAC.38.2.381. View

Lee S, Kriakov J, Vilcheze C, Dai Z, Hatfull G, Jacobs Jr W . Bxz1, a new generalized transducing phage for mycobacteria. FEMS Microbiol Lett. 2004; 241(2):271-6. DOI: 10.1016/j.femsle.2004.10.032. View

Min J, Park J, Lee Y, Kim S, Park J, Cho Y . Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease. Int J Tuberc Lung Dis. 2015; 19(10):1239-45. DOI: 10.5588/ijtld.14.0139. View

10.

Karpin G, Merola J, Falkinham 3rd J . Transition metal-α-amino acid complexes with antibiotic activity against Mycobacterium spp. Antimicrob Agents Chemother. 2013; 57(7):3434-6. PMC: 3697346. DOI: 10.1128/AAC.00452-13. View

11.

Douthwaite S, Aagaard C . Erythromycin binding is reduced in ribosomes with conformational alterations in the 23 S rRNA peptidyl transferase loop. J Mol Biol. 1993; 232(3):725-31. DOI: 10.1006/jmbi.1993.1426. View

12.

Doucet-Populaire F, Capobianco J, Zakula D, Jarlier V, Goldman R . Molecular basis of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis. J Antimicrob Chemother. 1998; 41(2):179-87. DOI: 10.1093/jac/41.2.179. View

13.

Prevots D, Shaw P, Strickland D, Jackson L, Raebel M, Blosky M . Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010; 182(7):970-6. PMC: 2970866. DOI: 10.1164/rccm.201002-0310OC. View

14.

Zumla A, Nahid P, Cole S . Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013; 12(5):388-404. DOI: 10.1038/nrd4001. View

15.

Wallace Jr R, Brown-Elliott B, McNulty S, Philley J, Killingley J, Wilson R . Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014; 146(2):276-282. PMC: 4694082. DOI: 10.1378/chest.13-2538. View

16.

Raviglione M, Ditiu L . Setting new targets in the fight against tuberculosis. Nat Med. 2013; 19(3):263. DOI: 10.1038/nm.3129. View